Comparison
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 vs 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Endogenous Maternal Derived Androgen and 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
A condition where hormones from the mother cross the placenta and cause atypical development in an XX fetus. It is present at birth. Management involves pediatric specialists and may include hormone therapy.
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
A rare condition affecting how certain hormones are processed in the body, which can influence sexual development. Treatment may involve hormone therapy and specialist care.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
Variable
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
0-16
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
severe
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
Chronic
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
No
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
reproductive
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
endocrine
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
endocrine
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
endocrine
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-endogenous-maternal-derived-androgen-C5679875 and 3-oxo-5-alpha-steroid-delta-4-dehydrogenase-deficiency-C0268297 differ in severity
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 | 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 | Discriminating power |
|---|---|---|---|
| Recognition timing | Described as present at birth, while the supplied onset axis is variable. | Supplied onset is 0–16 years; exact presentation is not established. | Moderate |
| Proposed hormone mechanism | Maternal-derived androgen crosses the placenta and affects an XX fetus. | The person’s processing of certain hormones is impaired. | High |
| Development pattern | Involves an XX fetus; specific genital findings are not listed. | May influence sexual development; karyotype and phenotype are unspecified. | Moderate |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 when
XX newborn with suspected maternal androgen exposure
This matches the stated placental-transfer mechanism and birth presentation.
Moderate
Maternal endocrine history is central
The source attributes the finding to endogenous maternal-derived androgen.
Moderate
Reproductive DSD classification is the main question
The record assigns a reproductive system and severe severity.
Low
Choose 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 when
An intrinsic hormone-processing disorder is suspected
The source describes altered hormone processing rather than maternal transfer.
Moderate
Features arise between birth and adolescence
The supplied onset axis is 0–16 years, without a precise age.
Low
Endocrine classification and moderate severity fit
The record assigns the endocrine system and moderate severity.
Low
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 | 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 | Interpretation |
|---|---|---|---|
| Karyotype | Source specifies an XX fetus. | Karyotype is not established in the source. | Confirmed XX status supports only the left concept; testing needs clinical context. |
| Maternal androgen evaluation | A maternal androgen source may be investigated; no cutoff is supplied. | Maternal transfer is not the stated mechanism. | Abnormal results are not diagnoses and require specialist interpretation. |
| Enzyme or genetic testing | Fetal enzyme deficiency is not described. | Named enzyme deficiency; confirmatory method is unspecified. | A specific confirmed result would favor the right concept, but absence of detail limits certainty. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
- Outcome
- Long-term outcome is not established; the record describes a chronic, severe condition.
- Factors
- Exposure timing and degree plus specialist care may matter, but effects are not quantified.
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
- Outcome
- Outcome is not established; the record describes a chronic, moderate condition.
- Factors
- Degree of hormone-processing impairment and specialist care may influence course.
Time frame: From birth or childhood into ongoing follow-up; no survival estimate is available.
Confirmed diagnosis, associated findings, and treatment response need individualized clinician interpretation.
Complications comparison
| Complication | Presentation |
|---|---|
| Atypical sexual development | Possible after prenatal androgen exposure; exact features are unlisted. Possible from altered hormone processing; exact features are unlisted. The sources do not establish a definitive complication list. |
| Long-term hormone care | Pediatric specialists may consider hormone therapy. Specialist care and hormone therapy may be used. No medication, dose, or treatment outcome is established. |
| Psychosocial burden | Severe classification may imply substantial burden, but course varies. Moderate classification does not predict an individual outcome. Severity labels should not be treated as prognosis. |
Patient education highlights
- HighConfirmation
An abnormal hormone result or atypical development requires specialist confirmation before either diagnosis is accepted.
- HighTreatment decisions
Do not start or adjust hormones independently; no doses or regimens are established here.
- MediumUncertainty
Ask which findings are confirmed, which are only suggestive, and what follow-up is planned.